

Nov-25-2008 08:13pm From:cooper&dunham

+212 391 0525

T-297 P.007/009 F-020

Applicants: Douglas J. M. Allen et al.
Serial No.: 10/716,098
Filed : November 17, 2003
Page 4

cancer, breast cancer, ovarian cancer, prostate cancer,
or colorectal cancer.

24. (Canceled)

25. (Previously Presented) The method of claim 23 further comprising administering to said mammal a therapeutically effective amount of a compound selected from the group consisting of alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell-cycle inhibitor, enzymes, topoisomerase, inhibitors, anti-hormones, and anti-androgens.

26. (Previously Presented) The method of claim 25 wherein the cell-cycle inhibitor is a mitotic inhibitor.

27. (Previously Presented) The pharmaceutical composition of claim 16, comprising from about 0.001 ~~mg~~ to about 100 mg/kg/day ~~mg~~ of N-(ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate and a pharmaceutically acceptable carrier.

Exam. Amdt.
12/1/08
TNT

28. (Previously Presented) The pharmaceutical composition of claim 16, comprising from about 0.001 ~~mg~~ to about 100 mg/kg/day ~~mg~~ of a hydrate form of N-(ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate and a pharmaceutically acceptable carrier.